Children with bronchiolitis often require hospital admission for supportive care including standard nasal cannula oxygen. At many hospitals, infants who require high-flow nasal cannula (HFNC) respiratory support must be admitted to an intensive care unit (ICU). More recently, however, studies have shown that the use of HFNC outside of the ICU setting is effective and well tolerated \[[@cit0001]--[@cit0004]\]. At our institution, infants with bronchiolitis who require HFNC may be admitted to a lower acute step-down ICU (SDU) at the attending physician's discretion. Historically, admission to the SDU has been used for infants felt to be at low risk for adverse events such as progression to continuous positive airway pressure (CPAP) support, bi-level positive airway pressure (BiPAP) support, or intubation. The evaluation of infants with bronchiolitis is difficult because of the subjective nature of assessing respiratory distress, and a recent study identified risk factors that predict the need for escalation of care beyond nasal cannula \[[@cit0005]\]. However, a small retrospective review that sought to predict which patients on HFNC would require increased respiratory support and intubation showed that easily identifiable markers such as patient age and history of prematurity were not predictive of failure among bronchiolitic patients being treated with HFNC \[[@cit0006]\].

We used a retrospective study design to evaluate the clinical characteristics and adverse events of infants on HFNC for bronchiolitis who were admitted to our standard ICU or our SDU. By assessing for differences in clinical characteristics and outcomes among patients admitted on HFNC to our ICU and SDU, we also sought to determine if clinicians could select a cohort of infants on HFNC who were at lower risk for adverse events. We included patients aged 1 month through 2 years admitted with bronchiolitis on HFNC and excluded those with significant prematurity or congenital heart or lung disease. Incidence of adverse outcomes was defined as a medical emergency team response, or escalation of respiratory support to CPAP, BiPAP, or intubation.

Sixty-one infants met our inclusion criteria and were admitted from the emergency department to the ICU (26 patients) or to the SDU (35 patients) on HFNC. Clinical characteristics and adverse events for each group are shown in [Table 1](#tab1){ref-type="table"}. The mean patient age was significantly lower in the ICU group compared with the SDU group (median 3.5 vs.9.8 months, *p*=0.045) and children admitted to the ICU had a higher initial flow of HFNC compared with those admitted to the SDU (median 8 L/min vs.6 L/min). The rate of adverse events was not different between those admitted to the ICU and those admitted to the SDU. Progression to CPAP or intubation occurred in only 2 patients in each group. Median hospital length of stay was 4 days for the ICU group and 3 days for the SDU group which was not statistically significant.

###### Admission on HFNC to the ICU versus the SDU

  ------------------------------------------------- ----------------- ----------------------- ---------
                                                    ICU  (*n* = 26)   Step down  (*n* = 35)   *p*
  Demographics                                                                                
  Race, *n* (%)                                                                               0.673
   White                                            9 (34.6)          14 (40.0)               
   African American                                 11 (42.3)         16 (45.7)               
   Other                                            6 (23.1)          5 (14.3)                
  Sex, male, *n* (%)                                17 (65.4)         19 (54.3)               0.383
  Age, months, median (IQR)                         3.5 (2.0--9.9)    9.8 (2.4--16.0)         0.045
  **Admission clinical characteristics**                                                      
  Documented tachypneic, yes, *n* (%)               20 (76.9)         29 (82.9)               0.564
  Documented retractions, yes, *n* (%)              24 (92.3)         33 (94.3)               1.000
  IV fluids started in **ED**, yes, *n* (%)         24 (92.3)         32 (91.4)               1.000
  **CXR** in ED, yes, n (%)                         23 (88.5)         25 (71.4)               0.128
  Viral process on CXR in ED,  yes, *n* (%)         11 (47.8)         18 (72.0)               0.087
   Infiltrate on CXR in ED, yes, *n* (%)            10 (43.5)         7 (28.0)                0.367
  Positive for **RSV**, yes, *n* (%)                16 (61.5)         18 (51.4)               0.432
  Received albuterol in ED, yes, *n* (%)            14 (53.9)         20 (57.1)               0.798
  Day of illness, median (IQR)                      3 (2--6)          3 (2--4)                0.231
  Litre of HFNC, median (IQR)                       8 (6--8)          6 (4--7)                \<0.001
  FiO~2~ of HFNC, median (IQR)                      45 (35--90)       40 (30--50)             0.149
  **Adverse outcomes**                                                                        
  **MET**, yes, *n* (%)                             0 (0.00)          2 (5.71)                0.503
  Progression to CPAP or intubation, yes, *n* (%)   2 (7.69)          2 (5.71)                1.000
  Hospital **LOS**, median (IQR)                    4 (3--5)          3 (3--6)                0.755
  Length of stay \>5 days, *n* (%)                  4 (15.4)          9 (25.7)                0.33
  ------------------------------------------------- ----------------- ----------------------- ---------

Note: HFNC, high-flow nasal canula; ICU, intensive care unit; SDU, step-down ICU; ED, emergency department; CXR, chest x-ray; RSV, Respiratory Syncytial Virus; MET, medical emergency team rapid response; LOS, length of stay.

There is growing literature to suggest HFNC is safe for use outside of an ICU setting. However, concerns remain that children who require HFNC may need escalation of care that prompts admission to an ICU. If clinicians could identify a lower risk cohort of infants with bronchiolitis who required HFNC, this could support the use of HFNC in selected cases outside of an ICU setting. In our study the incidence of adverse outcomes was low and was not clinically significant between patients admitted on HFNC to the ICU and those admitted on HFNC to the SDU. Our results, particularly our low rate of adverse events, were influenced because we excluded children with prematurity and pre-existing chronic lung or congenital heart disease. Our study had limited power to detect differences in adverse outcomes owing to its sample size. A larger study without exclusion criteria and increased frequency of adverse outcomes may be better able to assess whether clinician impression can identify low-risk children admitted on HFNC for bronchiolitis. Our results support the assertion that the evaluation of bronchiolitis remains subjective; despite this, our overall complication rate was low.
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